SCHEMBL3398339

SCHEMBL3398339

CCOC(=O)c1nc(-c2ccccc2)c2snc(-c3ccccc3F)c2c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
HSD17B10 Q99714 2/20 0.44
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
ADORA3 P0DMS8 3/20 0.41
HPGD P15428 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
CDC7 O00311 3/20 0.40
DBF4 Q9UBU7 3/20 0.40
DHODH Q02127 2/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
RARG P13631 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3404117 0.93 SCN9A (0.46) ALDH1A1HSD17B10JAK2JAK3HPGD
SCHEMBL3404102 0.91 JAK2 (0.44) ALDH1A1HSD17B10JAK2JAK3HPGD
SCHEMBL3401461 0.89 ALDH1A1 (0.51) ALDH1A1HSD17B10ADORA3HPGDNPSR1
SCHEMBL3407275 0.89 ALDH1A1 (0.51) ALDH1A1HSD17B10ADORA3HPGDNPSR1
SCHEMBL3404466 0.87 JAK2 (0.43) ALDH1A1HSD17B10JAK2JAK3HPGD
SCHEMBL3407905 0.85 CDC7 (0.53) ALDH1A1HSD17B10ADORA3HPGDNPSR1
SCHEMBL3401768 0.85 ALDH1A1 (0.49) ALDH1A1HSD17B10ADORA3HPGDNPSR1
SCHEMBL3405930 0.84 DHODH (0.48) ALDH1A1HSD17B10ADORA3HPGDNPSR1
SCHEMBL3405938 0.84 DHODH (0.49) ALDH1A1HSD17B10ADORA3HPGDMAPT
SCHEMBL3780077 0.83 CDC7 (0.48) ALDH1A1HSD17B10ADORA3HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9387200-B2 Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity FIBROGEN, INC. (US) 2016-07-12 US disclosed
US-20150209336-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN, INC. 2015-07-30 US disclosed
US-8952160-B2 Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity FIBROGEN, INC. (US) 2015-02-10 US disclosed
EP-2252619-B1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN INC (US) 2013-10-09 EP disclosed
US-20100330199-A1 ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN, INC. 2010-12-30 US disclosed
EP-2252619-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY Fibrogen, Inc. (US) 2010-11-24 EP disclosed
WO-2009089547-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY FIBROGEN, INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100330199-A1 ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY HIF1A, HIF1AN, EGLN3 ALDH1A1 256/4885HSD17B10 1231/4885JAK2 1596/4885
US-20150209336-A1 ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY HIF1A, HIF1AN, EGLN3 ALDH1A1 284/4885HSD17B10 1402/4885JAK2 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.